Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Murielle RousselBenjamin HebraudCyrille HulinAurore PerrotDenis CaillotAnne-Marie StoppaMargaret MacroMartine EscoffreBertrand ArnulfKarim BelhadjLionel KarlinLaurent GarderetThierry FaconShien GuoJosh WengSujith DhanasiriXavier LeleuPhilippe MoreauMichel AttalPublished in: Leukemia & lymphoma (2020)
The Intergroupe Francophone du Myelome 2009 trial (NCT01191060) assessed health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide/bortezomib/dexamethasone (RVd) induction therapy followed by consolidation therapy with either autologous stem cell transplantation (ASCT) plus RVd (RVd-ASCT) or RVd-alone; both groups then received lenalidomide maintenance therapy for 1 year. Global HRQoL, physical functioning, and role functioning scores significantly improved for both cohorts from baseline to the end of consolidation and were sustained during maintenance and follow-up, with clinically meaningful changes (RVd-alone: p = .0002; RVd-ASCT: p < .001). Similarly, both groups showed clinically meaningful improvements from baseline in fatigue, pain, and disease symptom scores. Side effects of treatment scores remained stable. In the RVd-ASCT group, there was transient worsening in HRQoL immediately after ASCT. These findings suggest that the clinical improvements observed with RVd-based treatment are accompanied by overall improvements in HRQoL for patients with NDMM.
Keyphrases
- multiple myeloma
- newly diagnosed
- stem cell transplantation
- high dose
- clinical trial
- study protocol
- randomized controlled trial
- bone marrow
- chronic pain
- mental health
- depressive symptoms
- cell therapy
- phase iii
- spinal cord
- mesenchymal stem cells
- sleep quality
- spinal cord injury
- blood brain barrier
- patient reported
- chronic lymphocytic leukemia